The object of Octapharma Biopharmaceuticals GmbH is contract research and development of therapeutic proteins produced in recombinantly modified human cell lines, as well as the development and operation of research platforms as a basis for Octapharma AG. The company provides these research and development services exclusively as a service to the group-affiliated Octapharma AG and is one of the central research entities of the Octapharma group. As of 31 December 2024 the company employed on average 190 employees; 131 were based in Heidelberg, 35 in Frankfurt and 29 in Berlin. The focus is on developing recombinant drugs as a modern alternative to plasma products with the aim of improved efficacy, tolerability, safety and extended half-life.
Die Entwicklung von humanen Zelllinien zur Herstellung von rekombinanten Proteinen als Therapeutikum sowie alle damit zusammenhängenden Geschäfte.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 714599 (as of 11 August 2026)
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 714599 (as of 11 August 2026)
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 714599 (as of 11 August 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Mannheim Local Court, HRB 714599 (as of 11 August 2026)
Sign in to view detailed salary and cost trends.
